BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis 2022-12-08 By admin
BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA 2022-11-16 By admin
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting 2022-11-01 By admin
BRIM Biotechnology Board of Directors approves seasoned equity offering of USD 18 million to accelerate phase 3 development of lead asset BRM421 for dry eye disease 2022-08-25 By admin
The road to regeneration: Could regenerative peptide therapy pave the way for new treatment methods for severe dry eye? 2022-06-23 By admin
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Disease 2022-05-17 By admin
